Cardiovascular pharmacotherapy in old age: how beneficial is it? what does it cost?
Gysling, E.
Praxis 84(44): 1248-1251
1995
ISSN/ISBN: 1661-8157 PMID: 7491446 Document Number: 446444
Because of their high morbidity and mortality, elderly people benefit most from drugs with a proven effect on disease complications and premature death. Thiazides, beta adrenergic blocking drugs, oral anticoagulants and aspirin are drugs that satisfy such criteria. These medications are comparatively well tolerated and cheap. They should not be neglected in favour of newer drugs with a less complete performance record.
Document emailed within 1 workday
Related Documents
de Ruijter, W.; Gussekloo, J. 2008: Cardiovascular prevention in the over-80 age group is not beneficial Nederlands Tijdschrift Voor Geneeskunde 152(1): 27Viberti, G.C. 2003: Rosiglitazone: potential beneficial impact on cardiovascular disease International Journal of Clinical Practice 57(2): 128-134
Van Gaal, L.F.; Wauters, M.A.; De Leeuw, I.H. 1997: The beneficial effects of modest weight loss on cardiovascular risk factors International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 21(Suppl 1): S5-S9
Widimský, J.; Skodová, Z. 1997: What are the trends in cardiovascular pharmacotherapy in recent years in patients after myocardial infarct? Vnitrni Lekarstvi 43(9): 580-583
Patton, M.L.; Gurll, N.J.; Reynolds, D.G.; Vargish, T. 1983: Adrenalectomy abolishes and cortisol restores naloxone's beneficial effects on cardiovascular function and survival in canine hemorrhagic shock Circulatory Shock 10(4): 317-327
Scheen, A.J. 2010: A patient with cardiovascular risk factors and comorbidities: integration of indications and contra-indications in pharmacotherapy Revue Medicale de Liege 65(7-8): 476-481
Anand, K.; Pandav, C.S. 1998: Cost-effectiveness of cardiovascular screening and intervention programmes National Medical Journal of India 11(1): 21-22
Marques-Vidal, P.; Bongard, V.; Arveiler, D.; Amouyel, P.; Ducimetière, P.; Ferrières, J. 2002: Medical cost of cardiovascular risk factors prevention in France Archives des Maladies du Coeur et des Vaisseaux 95(4): 275-281
Huang, G.; Gu, D.; Wu, X.; Duan, X.; Xu, X.; Wu, J.; Xie, B. 2000: Cost-effectiveness analysis of Beijing Fangshan cardiovascular prevention program in 1992 - 1997 Zhonghua Yu Fang Yi Xue Za Zhi 34(2): 78-80
Marques-Vidal, P.; Arveiler, D.; Amouyel, P.; Ducimetière, P.; Ferrières, J. 2001: Cost of cardiovascular risk factor prevention in middle-aged French men. The PRIME study Revue d'Epidemiologie et de Sante Publique 49(6): 541-549
Giesecke, H.; Meyer, F.P.; Walther, H. 1975: Problems of ambulatory pharmacotherapy. 6. Studies of the ambulatory pharmacotherapy of influenza Zeitschrift für Arztliche Fortbildung 69(23): 1201-1208
Talbert, R.L.; Gal, P.; Dukes, G.E.; Miller, W.A.; Porter, W.C.; Rush, D.R.; Schneider, P.; Vlasses, P.H.; Zarowitz, B.J. 1992: Pharmacotherapy specialty certification examination. II. Blueprint to examination. The Board of Pharmaceutical Specialties' Specialty Council on Pharmacotherapy PharmacoTherapy 12(6): 484-490
Shade, S.B.; Kevany, S.; Onono, M.; Ochieng, G.; Steinfeld, R.L.; Grossman, D.; Newmann, S.J.; Blat, C.; Bukusi, E.A.; Cohen, C.R. 2013: Cost, cost-efficiency and cost-effectiveness of integrated family planning and HIV services Aids 27(Suppl 1): S87-S92
Wagner, M.; Goetghebeur, M.; Merikle, E.; Pandya, A.; Chu, P.; Taylor, D.C.A. 2009: Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada Canadian Journal of Clinical Pharmacology 16(2): E331-E345
1999: Canadian Cardiovascular Society 1998 Consensus Conference on the Prevention of Cardiovascular Diseases: The Role of the Cardiovascular Specialist Canadian Journal of Cardiology 15 Suppl G: 1g
Hudecková, H.; Straka, S.; Szilágyiová, M.; Avdicová, M.; Rusnáková, S. 2002: Cost effectiveness and cost benefit of viral hepatitis B vaccination in the Slovak Republic Central European Journal of Public Health 10(4): 146-148
Mielck, A. 1988: Cost-effectiveness and cost-benefit approaches in programs designed to prevent AIDS Aids and Public Policy Journal 3(3): 19-22
Kahn, J.G.; Jiwani, A.; Gomez, G.B.; Hawkes, S.J.; Chesson, H.W.; Broutet, N.; Kamb, M.L.; Newman, L.M. 2014: The cost and cost-effectiveness of scaling up screening and treatment of syphilis in pregnancy: a model PLOS one 9(1): E87510
Tremblay, J. 1980: Prescription drugs and the aged: cost-free and cost-containment measures L'Union Medicale du Canada 109(3): 414-420
Wilson, L. 2008: The cost of errors. Medicare's new policy could cost the average hospital $23,772: study Modern Healthcare Suppl: 8-9